References
- Writing Group for the Women's Health Initia-tive Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal wo-men: principal results from the Women's Health Initiative randomised controlled trial. J Am Med Assoc 2002;288:321–33
- The Women's Health Initiative Steering Com-mittee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Con-trolled Trial. J Am Med Assoc 2004;291:1701–12
- Gambrell RD. The Women's Health Initiative Reports in perspective: facts or fallacies. Cli-macteric 2004;7:225–8
- Neves-e-Castro M. My dream. Climacteric 2004;7:322–3
- Maclennan AH, Sturdee DW. Time for new long-term trials of postmenopausal hormone therapies! Climacteric 2003;6:265–7
- The Writing Group of the IMS Executive Committee. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Climacteric 2004;7: 8–11
- Genazzani AR, Gambacciani M, Simoncini T, Schneider HPG. Hormone replacement therapy in climacteric and aging brain. Climacteric 2003;6:188–203
- Koh KK. Can a healthy endothelium influence the cardiovascular effects of hormone replace-ment therapy? Int J Cardiol 2003;87:1–8
- Million Women Collaborators. Breast cancer and hormone replacement in the Million Women Study. Lancet 2003;362:419–27
- Sturdee DW, MacLennan AH. Should epide-miology, the media and quangos determine clinical practice? Climacteric 2004;7:1–2